PT  - JOURNAL ARTICLE
AU  - Mungo, Chemtai
AU  - Bukusi, Elizabeth
AU  - Kirkland, Grace E
AU  - Ogollah, Cirillus
AU  - Rota, Gershon
AU  - Omoto, Jackton
AU  - Rahangdale, Lisa
TI  - Feasibility of adjuvant self-administered intravaginal 5-fluorouracil cream following primary treatment of cervical intraepithelial neoplasia grade 2 or 3 among women living with HIV in Kenya: study protocol for a pilot trial
AID  - 10.1101/2023.12.13.23299916
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.13.23299916
4099  - http://medrxiv.org/content/early/2023/12/14/2023.12.13.23299916.short
4100  - http://medrxiv.org/content/early/2023/12/14/2023.12.13.23299916.full
AB  - Background Women living with HIV (WLWH), the majority of whom live in low- and middle-income countries (LMICs), are at higher risk of cervical precancer, known as cervical intraepithelial neoplasia (CIN), and are up to six times more likely to get cervical cancer. Current CIN treatment methods, primarily ablation or excision, have high treatment failure rates among WLWH, up to 30% for CIN grade 2 or 3 (CIN2/3) at 24 months following ablation. Without strong follow-up many WLWH with treatment failure are at risk of developing invasive cervical cancer, highlighting the urgent need for improved CIN treatment methods. Prior studies in high-income countries (HICs) have demonstrated that 5-Fluorouracil (5-FU) cream, an antimetabolite drug that is easily accessible in LMICs, can be used intravaginally as adjuvant therapy following primary CIN2/3 treatment in WLWH to reduce CIN2/3 recurrence. While the safety, acceptability, and efficacy of self-administered 5-FU for cervical precancer treatment has been demonstrated in HICs, it has not been studied among WLWH in LMICs who bear the greatest burden of cervical cancer.Methods We are conducting a Phase I pilot study investigating the feasibility of using 5-FU cream as an adjuvant, self-administered intravaginal therapy following cervical intraepithelial neoplasia grade 2/3 (CIN2/3) treatment among WLWH in Kenya (ClinicalTrials.gov NCT05362955). Twelve participants will be enrolled in this single-arm study. Participants will self-administer 2g of 5% 5-FU cream intravaginally every other week for eight applications. The primary objective is to determine safety, defined as the type, frequency, and severity of adverse events (AEs) using a standardized grading scale. The secondary objectives are uptake, tolerability, adherence, and acceptability.Results There are no results at this time as this is an ongoing study.Discussion To achieve the World Health Organization (WHO) 90/70/90 global cervical cancer elimination goals, which include 90% of women with cervical precancer adequately treated by 2030, it is essential to employ innovative and resource-appropriate strategies to improve cervical precancer treatment among WLWH. The use of 5-FU as adjuvant therapy following current screen & treat programs may be a feasible and scalable strategy to optimize outcomes in this high-risk group. This clinical trial will provide important feasibility data to inform future randomized efficacy trials in LMICs.Trial registration ClinicalTrials.gov identifier: NCT05362955What uncertainties existed regarding feasibility?There are no uncertainties to report yet as the study is ongoing.What are the key feasibility findings?There are no key feasibility findings as the study is ongoing.What are the implications of the feasibility findings for the design of the main study?Feasibility findings from this trial that will inform the design of the future study include safety findings - frequency and severity of adverse events, which may necessitate a different dosing schedule for the main study, adherence findings - if low levels of adherence to self-administered therapies are established, the authors will work on designing strategies to improve adherence prior to moving to a larger study. Finally, acceptability findings including the levels of male partner support of the treatment will inform future study efforts.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05362955Funding StatementThis research was supported by the by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number K12HD103085 and the Victorias Secret Global Fund for Womens Cancers Career Development Award in Partnership with Pelotonia Foundation and the American Association of Cancer Research (AACR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The study funders have no role in the research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This clinical trial has full ethics review board approval from the University of North Carolina Chapel Hill, the Kenya Medical Research Institute.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsLMIClow- and middle-income countriesLCCCLineberger Comprehensive Cancer CenterDSMCData safety and monitoring committeeHIVhuman immunodeficiency virusWLWHwomen living with HIVHPVhuman papillomavirusARTantiretroviral therapyWHOWorld Health OrganizationLEEPLoop Electrosurgical Excision ProcedureCIN2/3cervical intraepithelial neoplasia grade 2 and 35-FU5-fluorouracilAEsadverse eventsDLTdose limiting toxicityIDIsin-depth interviews